Variable | Overall Survival | Progression-free Survival | ||
---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | |
Tumor site | ||||
Pyriform sinus | Reference | 0.160 | Reference | 0.051 |
Not pyriform sinus | 0.481 (0.173–1.336) | 0.394 (0.154–1.004) | ||
cT stage | ||||
T1–2 | Reference | 0.772 | Reference | 0.239 |
T3–4 | 1.149 (0.450–2.934) | 1.686 (0.707–4.019) | ||
Pathological stage | ||||
I + II + III | Reference | 0.227 | Reference | 0.038 |
IV | 2.174 (0.617–7.662) | 8.339 (1.119–62.132) | ||
Lymphovascular invasion | ||||
No | Reference | 0.036 | Reference | 0.020 |
Yes | 3.464 (1.084–11.075) | 3.367 (1.213–9.345) | ||
c-Jun expression | ||||
Low | Reference | 0.035 | Reference | 0.476 |
High | 3.313 (1.089–10.081) | 1.374 (0.573–3.295) |